Nura Bio gets $73.8M to advance SARM1 inhibitors for neurodegeneration

Nura Bio raises $73.8M Series B to advance oral SARM1 inhibitors NB-4746 in ALS and NB-9402 through early clinical trials.

Raccontata daendpoints.news